Results 221 to 230 of about 49,773 (253)
Some of the next articles are maybe not open access.
Value of the sodium-channel blocker challenge in Brugada syndrome
International Journal of Cardiology, 2017Intravenous drug challenge is frequently performed to unmask Brugada syndrome (BrS). However, its true sensitivity has never been assessed. We used the obligate BrS transmitters in families affected by BrS to evaluate the true accuracy of drug challenge.All consecutive patients from 2000 to 2014 who underwent drug challenge during familial screening ...
Dylan Therasse +10 more
openaire +3 more sources
Sodium Channel Blockers and Activators
2000Impulse conduction in brain and peripheral nerves, skeletal and cardiac muscle is sustained by transient increases in membrane permeability to sodium ions. This function resides in a family of integral membrane proteins, the voltage-gated Na+ channels.
openaire +1 more source
Sodium and Calcium Channel Blockers
2002The term “neuroprotection” means the pharmacologic prevention of the rapid (hours) or slower neuronal cell death caused by impaired blood flow or head trauma. Typically, neuroprotection is studied by acute drug treatment shortly after the insult in animal models of stroke, brain ischemia, or head trauma. The study of neuroprotection with organic cation
openaire +1 more source
The effects of calcium and calcium channel blockers on sodium pump
Pflügers Archiv European Journal of Physiology, 1995The effects of 10 mM Ca2+ and Ca2+ channel blockers verapamil, diltiazem and flunarizine on the ouabain-sensitive electrogenic Na+, K+ pump activity of mouse diaphragm muscle fibres enriched with Na+ were compared with the changes in cytosolic [Ca2+]. The electrogenic Na+ pump activity produced by adding K+ to muscles previously bathed for 4 h in a K(+)
T, Stankovicová +5 more
openaire +2 more sources
Comparison of known sodium-channel blockers in DFP toxicity
Toxicology Letters, 1985Research on potential therapeutic agents for organophosphate toxicity has traditionally been directed toward blocking the action of acetylcholine on its muscarinic receptors or on reactivating the inhibited catalytic enzyme. Here, we used a whole-animal lethality paradigm to study another potential antidotal mechanism: pharmacological disruption of the
openaire +2 more sources
New insights into the pharmacology of sodium channel blockers
European Heart Journal, 1992J, Tamargo, C, Valenzuela, E, Delpón
openaire +2 more sources
Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers
Expert Opinion on Investigational Drugs, 2020Kenneth D Candido +1 more
exaly
Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain
The Medical Letter on Drugs and TherapeuticsThe FDA has approved suzetrigine (Journavx – Vertex), a selective sodium channel blocker, for oral treatment of moderate to severe acute pain in adults. Suzetrigine is the first sodium channel blocker to be approved in the US for this indication and the first oral nonopioid drug to be approved for treatment of pain in over 25 years.
openaire +2 more sources